AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
HemaCare Corporation, Los Angeles, California, released a status report on patients who have continued to be treated in the company's clinical trial of Immupath for one year following the completion of Phase I/II clinical trials.
Immupath is a potential AIDS treatment which the company has been testing since 1990. The treatment involves giving patients hyperimmune plasma - with high titers of HIV-neutralizing antibodies - pooled from a large number of asymptomatic donors with HIV infection.
The Phase I/II clinical trial began in January 1991 when 220 patients were equally divided into 3 groups: placebo, half-strength Immupath, and …